8-K: Vivos Therapeutics Pivots Strategy Amid Q2 Losses

Vivos Therapeutics reports a significant increase in Q2 2025 operating losses to $4.9 million, driven by a strategic pivot and the acquisition of The Sleep Center of Nevada.

Summary

• Vivos Therapeutics reported total revenue of $3.8 million for Q2 2025, down from $4.1 million in Q2 2024, an expected decline due to a strategic shift in its sales and distribution model.
• Gross profit decreased to $2.1 million in Q2 2025 from $2.7 million in Q2 2024, with gross margin declining to 55% from 65%.
• Operating expenses surged by 52% to $7.0 million in Q2 2025, up from $4.6 million in the prior year, primarily due to professional fees for equity and debt financings related to the SCN acquisition and integration costs.
• The company's operating loss widened to $4.9 million in Q2 2025, compared to $1.9 million in Q2 2024.
• Net loss for the quarter was $5.013 million, an increase from $1.930 million in the same period last year.
• Cash and cash equivalents stood at $4.4 million as of June 30, 2025, down from $6.2 million at December 31, 2024.
• Stockholders' equity decreased to $4.6 million as of June 30, 2025, from $8.0 million at December 31, 2024.
• The company completed the acquisition of The Sleep Center of Nevada (SCN) on June 10, 2025, recognizing approximately $500,000 in diagnostic sleep testing services revenue from SCN in just 20 days post-acquisition.
• Vivos is implementing a new sleep practice management model, entering its first agreement with MISleep Solutions LLC on July 14, 2025, for a joint location in Auburn Hills, Michigan, expected to open in October 2025.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While current financial results show significant losses and increased expenses, these are presented as expected consequences of a strategic pivot that management believes will drive long-term growth. Early operational results from the acquired sleep center (SCN) are positive, showing strong demand. However, the success of this pivot is contingent on successful integration, further financing, and market acceptance, introducing considerable risk.

Positives

• The acquisition of The Sleep Center of Nevada (SCN) generated approximately $500,000 in diagnostic sleep testing services revenue in just 20 days post-acquisition, demonstrating immediate revenue contribution from the new model.
• Demand at SCN locations adapted to the Vivos model currently exceeds capacity, with patient appointments booked out for weeks and less than 40% of patients currently being served, validating the new direct-to-patient model.
• The company is actively exploring scaling its new sleep center alliance and acquisition model, indicating potential for future growth.
• The new sleep practice management model, exemplified by the MISleep Solutions LLC agreement, allows Vivos to expand its reach without full acquisitions, potentially increasing market penetration.

Negatives

• Total revenue declined to $3.8 million in Q2 2025 from $4.1 million in Q2 2024, reflecting a decrease in product and service revenue.
• Gross profit decreased to $2.1 million in Q2 2025 from $2.7 million in Q2 2024, with gross margin falling to 55% from 65%.
• Operating expenses increased significantly by 52% to $7.0 million in Q2 2025, driven by higher professional fees for financing and integration costs related to the SCN acquisition.
• The operating loss widened substantially to $4.9 million in Q2 2025, compared to $1.9 million in the prior year period.
• Net loss increased to $5.013 million in Q2 2025 from $1.930 million in Q2 2024.
• Cash and cash equivalents decreased to $4.4 million as of June 30, 2025, from $6.2 million at December 31, 2024, indicating cash burn.
• Stockholders' equity declined to $4.6 million as of June 30, 2025, from $8.0 million at December 31, 2024.
• The company incurred significant new debt, with total debt reaching approximately $7.9 million as of June 30, 2025, compared to zero at December 31, 2024.

Risks

• Risk that Vivos may be unable to successfully integrate SCN's business into its own or otherwise implement sales, marketing, and other strategies that increase revenues.
• Risk that some patients may not achieve the desired results from using Vivos products.
• Risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector.
• Risk that Vivos may be unable to secure additional financing to acquire additional sleep centers/practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing.
• Market and other conditions that could impact Vivos' business or ability to obtain financing.

Future Outlook

Vivos Therapeutics is confident that its strategic initiatives, including the acquisition of The Sleep Center of Nevada and the development of new sleep practice management models, have positioned the company for long-term growth. The company plans to scale its new model in the quarters ahead through additional sleep center alliances or acquisitions and expects to discuss anticipated effects on near-term revenue growth and cash burn in an upcoming conference call.

Management Comments

• "The second quarter of 2025 was a particularly important one in the history of Vivos."
• "This acquisition marked a pivot in our core sales, marketing, and distribution model from one reliant on dentists alone for subscription and product revenue to a more comprehensive model that allows us to capture both OSA diagnostic and treatment revenue via more direct relationships with the patients who desperately need cutting-edge OSA treatments like ours."
• "This pivot was coupled with our investment in SCN plus a continued weaning off of our legacy enrollment revenue streams, and our weaker comparative second quarter results reflect this."
• "However, we are thrilled with what we are seeing out of SCN, as we recognized approximately $500,000 of diagnostic sleep testing services revenue over just twenty days from the June 10 closing to the end of the quarter."
• "Moreover, demand at SCN locations adapted to our Vivos model so far continues to exceed our current capacity, with patient appointments booked out for weeks and less than 40% of patients currently being served. This validates our belief in our new model, and so we actively looking to scale this model in the quarters ahead with additional sleep center alliances or acquisitions."
• "So, in sum, we believe we are ably navigating our strategic business model pivot, and we are confident that future of Vivos is bright and that our strategic initiatives have positioned us for long term growth."

Industry Context

Vivos Therapeutics operates in the sleep-related breathing disorders market, specifically focusing on obstructive sleep apnea (OSA) treatment. The company's strategic pivot from a dentist-centric model to one involving direct patient relationships and acquisitions of medical sleep centers reflects a broader trend in healthcare towards integrated care models and direct-to-consumer approaches for chronic conditions. This shift aims to capture a larger share of the diagnostic and treatment revenue stream, addressing the significant unmet need in OSA diagnosis and treatment, where 90% of over 1 billion affected individuals remain undiagnosed. The move away from legacy treatments like CPAP towards addressing root causes aligns with a growing demand for non-surgical, non-invasive, and non-pharmaceutical solutions.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** Experience increased losses and potential dilution from future capital raises, but also potential for long-term value creation if the strategic pivot is successful. Current cash burn and debt increase financial risk.
• **Employees:** Integration of SCN and expansion of new models may lead to organizational restructuring and new opportunities.
• **Customers (Patients):** Benefit from expanded access to Vivos' OSA diagnostic and treatment options through the new sleep center model, potentially reducing wait times and improving care access.
• **Suppliers:** Potential for increased demand for Vivos' proprietary devices and services as the new model scales.
• **Creditors:** Increased exposure due to new debt taken on for the SCN acquisition, requiring successful execution of the new business model to ensure repayment capacity.

Next Steps

• Scale the new sleep center alliance and acquisition model in the quarters ahead.
• Explore similar management arrangements in other states following the MISleep Solutions LLC agreement.
• Open the joint location in Auburn Hills, Michigan, estimated for October 2025.
• Host an investor conference call on August 19, 2025, to discuss strategic collaborations, anticipated near-term revenue growth, and cash burn.
• File the Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025, with the SEC.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation, shifting its core business model. While the immediate financial results show increased losses and cash burn, these are explicitly stated as expected consequences of the pivot and the recent acquisition of The Sleep Center of Nevada. Early operational indicators from the acquired entity, such as high patient demand and initial revenue contribution, are positive and validate the new strategy. However, the success of this pivot is highly dependent on effective integration, successful scaling, and the ability to secure additional financing. Given the high execution risk and the current financial strain, a 'hold' recommendation is appropriate for existing investors to observe the progress of this strategic shift. For new investors, the current uncertainty and capital needs suggest a cautious approach until more concrete evidence of sustained profitability and successful scaling emerges.

Keywords

Obstructive Sleep Apnea, OSA, Sleep Disorders, Medical Device, Sleep Center Acquisition, Healthcare Technology, Financial Results, Q2 Earnings, Vivos Therapeutics, VVOS, Dental Sleep Medicine